2-Deoxy-D-Glucose as a Potential Antiviral and Anti-COVID-19 Drug

The search for effective therapeutics has been unyielding in the relentless battle against the COVID-19 pandemic. A potential drug candidate is 2-deoxyD-glucose (2-DG), which has been evaluated as a polypharmacological agent for antiviral therapy due to its influence on the glycolytic pathway. This chapter delves into the promising role of 2-deoxy-D-glucose (2-DG) as a potential anti-viral drug. With a focus on the biochemical and pharmacological aspects, this chapter explores how 2-DG may disrupt the viral life cycle and modulate host immune responses. An in-depth analysis of the current scientific evidence, including preclinical studies and clinical trials, will be highlighted to shed light on the drug's efficacy, safety, and potential as a treatment option. Furthermore, the challenges and prospects of 2-DG in the context of COVID-19 management will be elaborated. The COVID-19 pandemic has posed unprecedented challenges to global healthcare systems, demanding swift and innovative approaches to combat the virus. Amid this backdrop, the utilization of 2- deoxy-D-glucose (2-DG) as an anti-COVID-19 drug has emerged as a promising avenue for research and therapeutic development. This chapter offers an exhaustive exploration of the potential of 2-DG in the context of COVID-19 treatment. Additionally, action mechanisms and safety concerns associated with administering 2- DG in treating COVID-19 will be reviewed. This chapter aims to equip readers with a comprehensive understanding of 2-DG's role in the fight against COVID-19 and its place in the evolving the landscape of antiviral therapeutics.